US: Pharmaceuticals
featured
1999: Teva Pharmaceutical Industries Ltd receives FDA approval to market Plan B, the first emergency contraceptive drug for prescription-only use in the United States. 2005: Reproductive-rights groups file lawsuit in Brooklyn federal court seeking to force FDA to respond to their petition.
» Read MoreMore
-
1999: Teva Pharmaceutical Industries Ltd receives FDA approval to market Plan B, the first emergency contraceptive drug for prescription-only use in the United States. 2005: Reproductive-rights groups file lawsuit in Brooklyn federal court seeking to force FDA to respond to their petition.
-
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
-
LONDON, April 4- After a lengthy fight, Swiss drugmaker Roche Holding AG said it had agreed to hand over data from all clinical trials of its best-selling flu drug Tamiflu to a group of outside researchers. Sales of the drug hit close to $3 billion in 2009 due to the H1N1 swine flu pandemic, although they have since declined.
-
Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year.
-
CAMP HILL, Pa.-- Rite Aid's revenue from stores open at least a year fell 2 percent in March, as cheaper generic drugs continued to hurt the drugstore operator's performance. Rite Aid Corp., which is based in Camp Hill, Pa., had 4,621 stores as of March 30. In morning trading, Rite Aid shares slipped 4 cents, or 2.3 percent, to $1.71.
-
In addition to superbugs' deadly human toll, associated health costs run into the billions. Some warn that we may never win our war against them as research tapers off.
-
*Experts in daily talks on risks posed by new China virus. LONDON, April 4- Experts from around the world are in daily talks about the threat posed by a deadly new strain of bird flu in China, including discussions on if and when to start making a vaccine.
-
LONG BEACH, Calif.-- Obagi Medical Products Inc. said Wednesday that Canadian drugmaker Valeant Pharmaceuticals boosted its offer to buy the dermatology products maker, topping a bid made a day ago by a German rival.
-
*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland's Takeover Panel said on Wednesday.
-
*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland's Takeover Panel said on Wednesday.
-
At least three of the world's top drugmakers are bidding for Brazil's Ache Laboratorios Farmaceuticos in an auction that may value the group at more than $5 billion, people familiar with the matter said.
-
Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.
-
We look forward to continued engagement and successful collaboration with India on these issues, "said Andrea Mead, a spokeswoman for the U.S.
-
*Optimer could get $15- $16/ shr- analyst. April 2- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker. The report also named AstraZeneca PLC and Japan's Astellas Pharma Inc as potential buyers.
-
Andrew Weiss, head of pharma and biotech research at Vontobel, tells CNBC why Novartis' failure to win its battle for patent protection for the drug Glivec highlights the flaws in pharma companies' emerging market strategy.
-
LONDON/ MUMBAI, April 2- Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016..
-
Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.
-
MUMBAI/ NEW DELHI, April 1- India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
-
NEW DELHI, April 1- The Indian government hailed as "historic" a Supreme Court ruling on Monday against a plea by Swiss drugmaker Novartis AG to protect the patent on its drug Glivec.
-
MUMBAI, April 1- Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.